Business:
Oncolytic Virus
Drug notes:
Also combo Clin2 bladder cancer, combo Clin1 bladder cancer
About:
CG Oncology is developing oncolytic immunotherapies to treat patients with advanced bladder cancer. Bladder cancer is the 4th most common form of cancer in men in the US. To address this CG is genetically engineering oncolytic immunotherapies. The therapy has a dual mechanism of action: first, the therapy infects and replicates inside tumor cells causing cell lysis. Secondly, the rupturing of cancer cells releases tumor-derived antigens that stimulates a systemic anti-tumor immune response. CG has 3 active clinical programs with their lead candidate, CG0070, showing remarkable efficacy in bladder cancer patients in their clinical trials.
Manager, Quality Control United States|8 days ago
Associate Director, Quality Control United States|8 days ago
Associate Director, PMO United States|12 days ago
Manager, SOX Compliance United States|52 days ago
Medical Director (Urology) - US Based/Remote United States|65 days ago
Health Systems Director United States|80 days ago
Clinical Trials Associate (CTA) United States|Not provided